BR112021017892A8 - Terapias de combinação anti-cancer compreedendo agentes bloqueadores de ctla-4 e pd-1 - Google Patents
Terapias de combinação anti-cancer compreedendo agentes bloqueadores de ctla-4 e pd-1Info
- Publication number
- BR112021017892A8 BR112021017892A8 BR112021017892A BR112021017892A BR112021017892A8 BR 112021017892 A8 BR112021017892 A8 BR 112021017892A8 BR 112021017892 A BR112021017892 A BR 112021017892A BR 112021017892 A BR112021017892 A BR 112021017892A BR 112021017892 A8 BR112021017892 A8 BR 112021017892A8
- Authority
- BR
- Brazil
- Prior art keywords
- ctla
- combination therapies
- blocking agents
- cancer combination
- blocking agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
TERAPIAS DE COMBINAÇÃO ANTI-CANCER COMPREEDENDO AGENTES BLOQUEADORES DE CTLA-4 E PD-1. São divulgadas terapias de combinação anti-câncer compreendendo um agente bloqueador de CTLA-4 e um agente bloqueador de PD-1. Em particular, as terapias de combinação são divulgadas em que o agente bloqueador de CTLA-4 é um anticorpo anti-CTLA-4 efetor silencioso ou fragmento de anticorpo anti-CTLA-4 efetor silencioso e o agente bloqueador de PD-1 é um anticorpo anti-PD-1 ou anti-PD-L1, ou fragmento de anticorpo dos mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962817749P | 2019-03-13 | 2019-03-13 | |
PCT/US2020/021783 WO2020185722A2 (en) | 2019-03-13 | 2020-03-10 | Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112021017892A2 BR112021017892A2 (pt) | 2021-12-07 |
BR112021017892A8 true BR112021017892A8 (pt) | 2023-01-31 |
Family
ID=72426465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021017892A BR112021017892A8 (pt) | 2019-03-13 | 2020-03-10 | Terapias de combinação anti-cancer compreedendo agentes bloqueadores de ctla-4 e pd-1 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220411507A1 (pt) |
EP (1) | EP3937979A4 (pt) |
JP (1) | JP2022525071A (pt) |
KR (1) | KR20210141539A (pt) |
CN (1) | CN113631189A (pt) |
AU (1) | AU2020234785A1 (pt) |
BR (1) | BR112021017892A8 (pt) |
CA (1) | CA3132198A1 (pt) |
MA (1) | MA55316A (pt) |
MX (1) | MX2021010997A (pt) |
WO (1) | WO2020185722A2 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021259426B2 (en) | 2020-04-22 | 2024-05-16 | Merck Sharp & Dohme Corp. | Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer |
CN116761889A (zh) * | 2021-01-29 | 2023-09-15 | 明慧医药(杭州)有限公司 | 抗原结合蛋白及其用途 |
US20240199741A1 (en) * | 2021-04-14 | 2024-06-20 | Akeso Pharmaceuticals, Inc. | Use of antibody in anti-tumor treatment |
CN117203235A (zh) * | 2021-04-21 | 2023-12-08 | 和铂医药(上海)有限责任公司 | 结合ctla-4的抗体及其用途 |
KR20230110141A (ko) | 2022-01-14 | 2023-07-21 | 영남대학교 산학협력단 | PD-L1 단백질에 특이적으로 결합하는 Fab 단편 및 이의 용도 |
WO2023217987A1 (en) * | 2022-05-12 | 2023-11-16 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
EP3142697A1 (en) * | 2014-05-15 | 2017-03-22 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
WO2018183408A1 (en) * | 2017-03-31 | 2018-10-04 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody |
-
2020
- 2020-03-10 US US17/436,857 patent/US20220411507A1/en active Pending
- 2020-03-10 MA MA055316A patent/MA55316A/fr unknown
- 2020-03-10 BR BR112021017892A patent/BR112021017892A8/pt unknown
- 2020-03-10 JP JP2021553837A patent/JP2022525071A/ja active Pending
- 2020-03-10 KR KR1020217032365A patent/KR20210141539A/ko unknown
- 2020-03-10 CN CN202080020847.XA patent/CN113631189A/zh active Pending
- 2020-03-10 EP EP20770048.5A patent/EP3937979A4/en active Pending
- 2020-03-10 MX MX2021010997A patent/MX2021010997A/es unknown
- 2020-03-10 CA CA3132198A patent/CA3132198A1/en active Pending
- 2020-03-10 WO PCT/US2020/021783 patent/WO2020185722A2/en unknown
- 2020-03-10 AU AU2020234785A patent/AU2020234785A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020185722A3 (en) | 2020-11-12 |
AU2020234785A1 (en) | 2021-08-19 |
US20220411507A1 (en) | 2022-12-29 |
CN113631189A (zh) | 2021-11-09 |
KR20210141539A (ko) | 2021-11-23 |
EP3937979A2 (en) | 2022-01-19 |
MX2021010997A (es) | 2021-10-01 |
CA3132198A1 (en) | 2020-09-17 |
EP3937979A4 (en) | 2023-03-08 |
BR112021017892A2 (pt) | 2021-12-07 |
MA55316A (fr) | 2022-01-19 |
WO2020185722A2 (en) | 2020-09-17 |
JP2022525071A (ja) | 2022-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021017892A8 (pt) | Terapias de combinação anti-cancer compreedendo agentes bloqueadores de ctla-4 e pd-1 | |
BR112019005823A2 (pt) | tratamento para enxaqueca refratária | |
EP3746119A4 (en) | METHODS FOR THE TREATMENT OF CANCER OR AN INFECTION USING A COMBINATION OF AN ANTI-PD -1 ANTIBODY, AN ANTI-LAG3 ANTIBODY AND AN ANTI-TIGIT ANTIBODY | |
CY1124730T1 (el) | Αντισωματα εναντι pd-1 και χρησεις αυτων | |
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
BR112019008861A2 (pt) | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) | |
BR112022004474A2 (pt) | Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta | |
JOP20200003B1 (ar) | أجسام مضادة ثنائية النوعية مثبطة لنقاط مراقبة المناعة | |
WO2018222722A3 (en) | COMPOSITIONS COMPRISING ANTI-LAG-3 ANTIBODY OR ANTI-LAG-3 ANTIBODY AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY | |
CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
BR112018002274A2 (pt) | anticorpos anti-pd-1 | |
BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
EP3760229A3 (en) | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent | |
BR112017020002A2 (pt) | Combinação de inibidor de hdac e anticorpo anti- pd-1 para o tratamento de câncer | |
EA201990374A1 (ru) | Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков | |
BR112019004995A2 (pt) | anticorpo que se liga especificamente a pd-1 e fragmento funcional do mesmo | |
CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
AU2018267843A1 (en) | PD-L1 antibody pharmaceutical composition and use thereof | |
EP3922647A4 (en) | ANTI-PD-1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | |
EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
EP4079760A3 (en) | Antibodies against clostridium difficile toxins and methods of using the same | |
MX2021010119A (es) | Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1. | |
WO2020106358A8 (en) | Novel anti-zika virus antibodies and uses thereof | |
EA202092967A1 (ru) | Схемы приема иммуноконъюгата антитела против cd37 | |
MX2021004226A (es) | Terapia combinada contra el cáncer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |